Evaluate Severe Hepatic Impairment on Dacomitinib PK

Status:
Completed

Trial end date:
2019-10-24

Target enrollment:

Participant gender:

This is a post approval requirement to study the effect of severe hepatic impairment on the pharmacokinetics of dacomitinib.

Phase 1

Pfizer